First test: how a cancer drug handles a damaged liver
NCT ID NCT06740799
Summary
This early-stage study aims to understand how a single dose of the drug quizartinib is processed by the body in people with severe liver impairment. It will compare 12 participants with poor liver function to healthy volunteers, measuring drug levels in the blood and checking for side effects. The goal is to gather basic safety and dosing information for future use in this population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Pharma
RECRUITINGMiami, Florida, 33147, United States
-
Clinical Pharmacology of Miami, LLC
RECRUITINGMiami, Florida, 33014, United States
-
GCP Research
RECRUITINGSt. Petersburg, Florida, 33705, United States
Conditions
Explore the condition pages connected to this study.